Pacira Pharmaceuticals (PCRX) saw its stock price plummet by 13.37% during intraday trading on Friday, as investors reacted to the company's preliminary FY25 revenue results.
The sharp decline followed the release of the preliminary financial results, which likely fell short of market expectations. The healthcare sector was already under pressure, with health care stocks dipping by 0.5% on Friday, adding to the downward momentum for PCRX.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments